Key facts
- Linnaeus Therapeutics’s last known valuation is $83.1M (Apr 2026).
- It has raised $35.6M across 8 recorded rounds; the latest was Seed Round ($5.0M) in Feb 2026.
- Notable investors include Springboard Enterprises, Kairos Ventures, National Cancer Institute, National Institute for Allergy and Infectious Disease, Penn Center for Innovation — 8 tracked in total.
- Linnaeus Therapeutics has filed 9 Form Ds with the SEC since 2018, most recently Mar 2026 ($4.8M sold to 25 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Linnaeus Therapeutics
Funding rounds
8 roundsAbout Linnaeus Therapeutics
Developer of molecular therapeutics designed to treat cancer and skin pigmentation disorders. The company's therapeutics utilize small-molecule agents to increase or decrease the amount of melanin pigment produced by skin cells, enabling medical practitioners to treat cancer and skin pigmentation disorders due to oncogenic mutations effectively.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Haddonfield, NJ, United States
- Founded
- 2016
- Employees
- 5
- Website
- linnaeustx.com/
- Ownership
- Privately Held (backing)
Linnaeus Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Linnaeus Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Linnaeus Therapeutics in its N-PORT filings yet. We sweep new filings monthly.